Velpatasvir-d3

O=C(OC)N[C@@H](C(C)C)C(N1[C@@H](C2=NC3=CC=C4C=C5C(OCC6=C5C=CC(C7=CNC([C@H]8N(C([C@H](NC(OC([2H])([2H])[2H])=O)C9=CC=CC=C9)=O)C[C@@H](COC)C8)=N7)=C6)=CC4=C3N2)CC[C@@H]1C)=O

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Yasmeen S, et al. An insight into the hepatoprotective role of Velpatasvir and Sofosbuvir per se and in combination against carbon tetrachloride-induced hepatic fibrosis in rats. Environ Sci Pollut Res Int. 2023 Sep;30 (42) :95660-95672.|[3]Lawitz EJ et al. Clinical Resistance to Velpatasvir (GS-5816), a Novel Pan-Genotypic Inhibitor of the Hepatitis C Virus NS5A Protein. Antimicrob Agents Chemother. 2016 Aug 22;60 (9) :5368-78.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.